Enhertu Gets US Approval for 1st-Line HER2+ Breast Cancer

TL;DR

AstraZeneca's Enhertu approved for 1st-line HER2+ breast cancer in the US.

AI Summary

AstraZeneca PLC announced on December 16, 2025, that its drug Enhertu has received US approval for first-line treatment of HER2-positive metastatic breast cancer. This approval expands the use of Enhertu, a collaboration with Daiichi Sankyo, to a new patient population.

Why It Matters

This expanded indication for Enhertu could significantly increase its market potential and provide a new, earlier treatment option for a substantial number of breast cancer patients.

Risk Assessment

Risk Level: low — This is a routine regulatory filing announcing an approved drug indication, which is generally positive news.

Key Players & Entities

• AstraZeneca PLC (company) — Registrant
• Enhertu (drug) — Approved medication
• Daiichi Sankyo (company) — Collaboration partner for Enhertu
• December 16, 2025 (date) — Date of announcement
• US (location) — Jurisdiction of approval

FAQ

From the Filing

0001654954-25-013970.txt : 20251216 0001654954-25-013970.hdr.sgml : 20251216 20251216061951 ACCESSION NUMBER: 0001654954-25-013970 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251216 FILED AS OF DATE: 20251216 DATE AS OF CHANGE: 20251216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251573309 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a6719l.htm ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC a6719l FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of December 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________     AstraZeneca PLC   INDEX TO EXHIBITS     1. Enhertu approved in US for 1L HER2+ metastatic BC   16 December 2025   Enhertu   plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer   Based on DESTINY-Breast09 Phase III trial results that showed AstraZeneca and Daiichi Sankyo's Enhertu in combination with pertuzumab reduced the risk of disease progression or death by 44% vs. THP with a median progression-free survival of more than three years   AstraZeneca and Daiichi Sankyo's  Enhertu  (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, as determined by a Food and Drug Administration (FDA)-approved test.   The approval follows  Priority Review  and Breakthrough Therapy Designation by the FDA and is based on the results of the DESTINY-Breast09 Phase III trial. The data were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in  The New England Journal of Medicine . 1   Sara Tolaney, MD, MPH, Chief of the Division of Breast Oncology, Dana-Farber Cancer Institute and principal investigator for the trial, said: "Trastuzumab deruxtecan plus pertuzumab is the only 1st-line treatment approved in more than a decade to demonstrate a statistically significant improvement in progression-fr